Jeffrey L. Jorgensen

18.8k citations

197 papers · 8.2k indexed · h-index 46

Hematology top 0.2%
- Acute Myeloid Leukemia Research 52
- Chronic Myeloid Leukemia Treatments 37
Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 65
- Myeloproliferative Neoplasms: Diagnosis and Treatment 19
Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 81
Immunology top 0.5%
Oncology top 1%
- CAR-T cell therapy research 16
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 56
Dermatology
- Cutaneous lymphoproliferative disorders research 17

Co-authors: Mark M. Davis L. Jeffrey Medeiros Hagop M. Kantarjian Farhad Ravandi Philip A. Reay Jörge E. Cortes Susan O’Brien Sa A. Wang
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: Nature (1 paper)The Lancet (1 paper)Journal of the American Chemical Society (1 paper)
Partner nations: United States China United Kingdom

In The Last Decade

Jeffrey L. Jorgensen

191 papers receiving 8.1k citations

Peers

Countries citing papers authored by Jeffrey L. Jorgensen

Since Specialization

Citations

This map shows the geographic impact of Jeffrey L. Jorgensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey L. Jorgensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey L. Jorgensen more than expected).

Fields of papers citing papers by Jeffrey L. Jorgensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey L. Jorgensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey L. Jorgensen. The network helps show where Jeffrey L. Jorgensen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jeffrey L. Jorgensen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeffrey L. Jorgensen Line = papers co-authored together Jeffrey L. Jorgensen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia Leukemia & lymphoma ·Jennifer Marvin‐Peek,Wei‐Ying Jen,Hagop M. Kantarjian,David McCue,Fadi Haddad,William G. Wierda,Alessandra Ferrajoli,Jan A. Burger,Tareq Abusab,Jeffrey L. Jorgensen,Sa A. Wang,Keyur Patel,Sanam Loghavi,Susan O’Brien,Farhad Ravandi	2024	4
2	Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection Cytometry Part B Clinical Cytometry ·Sa A. Wang,Jeffrey L. Jorgensen,Shimin Hu,Fuli Jia,Shaoying Li,Sanam Loghavi,Chi Young Ok,Beenu Thakral,Jie Xu,L. Jeffrey Medeiros,Wei Wang	2023	10
3	Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD Leukemia ·Philip A. Thompson,Michael J. Keating,Alessandra Ferrajoli,Nitin Jain,Christine B. Peterson,Naveen Garg,Sa A. Wang,Jeffrey L. Jorgensen,Tapan M. Kadia,Prithviraj Bose,Naveen Pemmaraju,Nicholas J. Short,William G. Wierda	2023	2
4	Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission Blood ·Elias Jabbour,Fadi Haddad,Nicholas J. Short,Jayastu Senapati,Nitin Jain,Koji Sasaki,Jeffrey L. Jorgensen,Sa A. Wang,Yesid Alvarado,Xuemei Wang,Courtney D. DiNardo,Lucia Masárová,Tapan M. Kadia,Rebecca Garris,Farhad Ravandi,Hagop M. Kantarjian	2023	25
5	Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results American Journal of Hematology ·Hagop M. Kantarjian,Nicholas J. Short,Nitin Jain,Koji Sasaki,Xuelin Huang,Fadi Haddad,Issa F. Khouri,Courtney D. DiNardo,Naveen Pemmaraju,William G. Wierda,Guillermo Garcia‐Manero,Partow Kebriaei,Rebecca Garris,Sanam Loghavi,Jeffrey L. Jorgensen,Monica Kwari,Susan O’Brien,Farhad Ravandi,Elias Jabbour	2023	45
6	Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higher American Journal of Hematology ·Elias Jabbour,Nicholas J. Short,Nitin Jain,Nadya Jammal,Jeffrey L. Jorgensen,Sa Wang,Xuemei Wang,Maro Ohanian,Yesid Alvarado,Tapan M. Kadia,Koji Sasaki,Rebecca Garris,Guillermo Garcia‐Manero,Farhad Ravandi,Hagop M. Kantarjian	2022	23
7	Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML Blood ·Sergej Konoplev,Guilin Tang,Xiaoqiong Wang,Wei Wang,Beenu Thakral,Jie Xu,Sherry Pierce,Jeffrey L. Jorgensen,Farhad Ravandi,Ghayas C. Issa,Olga Pozdnyakova,Sa A. Wang,Robert P. Hasserjian	2021	1
8	Tumor infiltrating lymphocyte grade in Merkel cell carcinoma: relationships with clinical factors and independent prognostic value Acta Oncologica ·Mehran Yusuf,Jeremy Gaskins,Steven F. Mandish,M.E. May,Weston Wall,William S. Fisher,Paul Tennant,Jeffrey L. Jorgensen,Jeffrey M. Bumpous,Neal Dunlap	2020	7
9	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML Blood Advances ·Nicholas J. Short,Hind Rafei,Naval Daver,Hyunsoo Hwang,Jing Ning,Jeffrey L. Jorgensen,Tapan M. Kadia,Courtney D. DiNardo,Sa A. Wang,Elias Jabbour,Uday Popat,Betül Oran,Jörge E. Cortes,Marina Konopleva,Musa Yılmaz,Ghayas C. Issa,Hagop M. Kantarjian,Farhad Ravandi	2020	22
10	Immune status and the efficacy of adjuvant radiotherapy for patients with localized Merkel cell carcinoma of the head and neck Clinical & Translational Oncology ·Mehran Yusuf,Jeremy Gaskins,M.E. May,Steven F. Mandish,Weston Wall,William S. Fisher,Paul Tennant,Jeffrey L. Jorgensen,Jeffrey M. Bumpous,Neal Dunlap	2020	1
11	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes Blood ·Nicholas J. Short,Hagop M. Kantarjian,Keyur P. Patel,Steven M. Kornblau,Jeffrey L. Jorgensen,Sa A. Wang,Marina Konopleva,Nitin Jain,Partow Kebriaei,Musa Yılmaz,Ghayas C. Issa,Jairo Matthews,Munazza Noor,Rebecca Garris,Farhad Ravandi,Elias Jabbour	2020	5
12	Early detection of transformation to BPDCN in a patient with MDS Experimental Hematology and Oncology ·Kamal Chamoun,Sanam Loghavi,Naveen Pemmaraju,Marina Konopleva,Michael H. Kroll,Madeleine Nguyen-Cao,Marisa Hornbaker,Courtney D. DiNardo,Tapan M. Kadia,Jeffrey L. Jorgensen,Michael Andreeff,Shimin Hu,Christopher B. Benton	2018	13
13	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study The Lancet Haematology ·Elias Jabbour,Nicholas J. Short,Farhad Ravandi,Xuelin Huang,Naval Daver,Courtney D. DiNardo,Marina Konopleva,Naveen Pemmaraju,William G. Wierda,Guillermo Garcia‐Manero,Koji Sasaki,Jörge E. Cortes,Rebecca Garris,Joseph D. Khoury,Jeffrey L. Jorgensen,Nitin Jain,Joie Alvarez,Susan O’Brien,Hagop M. Kantarjian	2018	160
14	CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia Blood ·Evgeniya Angelova,Charlene A. Audette,Yelena Kovtun,Naval Daver,Sa A. Wang,Sherry Pierce,Sergej Konoplev,Jeffrey L. Jorgensen,Marina Konopleva,Patrick A. Zweidler‐McKay,Hagop M. Kantarjian,Elias Jabbour,Joseph D. Khoury	2017	2
15	Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents Journal of Clinical Pathology ·Lanshan Huang,Guillermo Garcia‐Manero,Elias Jabbour,Maitrayee Goswami,Mark J. Routbort,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa A. Wang	2016	7
16	Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC) Clinical Lymphoma Myeloma & Leukemia ·Courtney D. DiNardo,Sarah A. Bannon,Mark J. Routbort,Anna R. Franklin,Maureen E. Mork,Mary Armanios,Emily M. Mace,Jordan S. Orange,Meselle Jeff‐Eke,Jane E. Churpek,Koichi Takahashi,Jeffrey L. Jorgensen,Guillermo Garcia‐Manero,Steve Kornblau,Alison A. Bertuch,Hannah Cheung,Kapil N. Bhalla,P. Andrew Futreal,Lucy A. Godley,Keyur P. Patel	2016	66
17	Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients Human Pathology ·Mariko Yabe,L. Jeffrey Medeiros,Guilin Tang,Sa A. Wang,Keyur P. Patel,Mark J. Routbort,Govind Bhagat,Carlos E. Bueso‐Ramos,Jeffrey L. Jorgensen,Rajyalakshmi Luthra,Weina Chen,Tariq Muzzafar,Rashmi Kanagal‐Shamanna,Joseph D. Khoury,Yahya Daneshbod,Masoud Davanlou,Shaoying Li,Ken H. Young,Roberto N. Miranda	2015	11
18	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response European Journal Of Haematology ·Qi Shen,Juan Ouyang,Guilin Tang,Elias Jabbour,Guillermo Garcia‐Manero,Mark J. Routbort,Sergej Konoplev,Carlos E. Bueso‐Ramos,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa A. Wang	2014	24
19	Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China. Archives of Pathology & Laboratory Medicine ·Ting Li,L. Jeffrey Medeiros,Pei Lin,Hongfang Yin,Martin Littlejohn,Whan Im,Patrick A. Lennon,Peter Hu,Jeffrey L. Jorgensen,Mei Liang,Hua Guo,Changhong Yin	2010	7
20	AIDS-Related Systemic Non-Hodgkin's Lymphoma at a Large Community Program AIDS Research and Human Retroviruses ·Regis A. Vilchez,Claudia A. Kozinetz,Jeffrey L. Jorgensen,Michael H. Kroll,Janet S. Butel	2002	17

About Jeffrey L. Jorgensen

Jeffrey L. Jorgensen is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 197 papers that have together received 8.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (65 papers), Acute Lymphoblastic Leukemia research (56 papers), Acute Myeloid Leukemia Research (52 papers), Chronic Myeloid Leukemia Treatments (37 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Cutaneous lymphoproliferative disorders research (17 papers) and CAR-T cell therapy research (16 papers). The work is most often cited by research in Hematology (2.9k citations), Genetics (2.0k citations) and Pathology and Forensic Medicine (2.5k citations). Jeffrey L. Jorgensen has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Mark M. Davis, L. Jeffrey Medeiros, Hagop M. Kantarjian, Farhad Ravandi, Philip A. Reay, Jörge E. Cortes, Susan O’Brien, Sa A. Wang, Stefan Faderl and Deborah A. Thomas. Their work appears in journals such as Nature, The Lancet and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact